AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29667496 — intervention group
Group type: EXPERIMENTAL
Intervention: INT-SIT (sitting interrupted hourly with 20 min light-intensity treadmill desk walking at 1.2-3.5 km/h)
Number of subjects: 24
Study 29667496 — intervention group
Group type: COMPARATOR
Intervention: SIT (prolonged sitting)
Number of subjects: 24
Study 29667496 — intervention group
Group type: EXPERIMENTAL
Intervention: INT-SIT
Number of subjects: 24
Study 27043671 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/amlodipine fixed combination 20/5mg
Number of subjects: 221
Study 27043671 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 20 mg
Number of subjects: 221
Study 27043671 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 221
Study 25524339 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 2401
Study 22707251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg via gum)
Number of subjects: 11
Study 22707251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 11
Study 20647100 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray mineral trioxide aggregate (GMTA)
Number of subjects: 40
Study 20647100 — intervention group
Group type: COMPARATOR
Intervention: White mineral trioxide aggregate (WMTA)
Number of subjects: 40
Study 20647100 — intervention group
Group type: COMPARATOR
Intervention: Water-to-powder (WP) ratios
Number of subjects: 40
Study 20647100 — intervention group
Group type: COMPARATOR
Intervention: Interaction between WP ratio and material type
Number of subjects: 40
Study 17852806 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day for 5 days
Number of subjects: 24
Study 17852806 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days (control for losartan)
Number of subjects: 24
Study 17852806 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg three times a day for 4 days and a single dose on day 5
Number of subjects: 24
Study 17852806 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 days and a single dose on day 5 (control for indomethacin)
Number of subjects: 24
Study 15819388 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (10 mg)
Number of subjects: 100
Study 15819388 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol fumarate (5 mg)
Number of subjects: 100
Study 15819388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (5 mg)
Number of subjects: 100
Study 15819388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12885748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated-fat dietary intervention from infancy until 5 years of age
Number of subjects: 1062
Study 10850385 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus interferon (CIFN)
Number of subjects: 472
Study 10850385 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2b (IFN alfa‐2b)
Number of subjects: 472
Study 10850385 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 3
Number of subjects: 472
Study 10850385 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 2
Number of subjects: 472
Study 10850385 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 1
Number of subjects: 472
Study 10850385 — intervention group
Group type: EXPERIMENTAL
Intervention: Virological sustained responders
Number of subjects: 472
Study 10850385 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsers
Number of subjects: 472
Study 8555143 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-retained mandibular overdentures and a new maxillary denture
Number of subjects: 150
Study 8555143 — intervention group
Group type: COMPARATOR
Intervention: New set of complete dentures
Number of subjects: 150
Study 2289472 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (4.5 mg)
Number of subjects: 36
Study 2289472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 6771653 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin-complex concentrates (Konyne)
Number of subjects: 51
Study 6771653 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin-complex concentrates (Proplex)
Number of subjects: 51
Study 6771653 — intervention group
Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 51
Study 31589323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin (10 mg twice daily) plus nicotine patch (21 mg)
Number of subjects: 61
Study 31589323 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nicotine patch (21 mg)
Number of subjects: 61
Study 31765422 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based health education provided by community health volunteers (CHVs) with weekly supplements and follow-ups.
Number of subjects: 340
Study 31765422 — intervention group
Group type: COMPARATOR
Intervention: Control group received IFAS health education from healthcare providers.
Number of subjects: 340
Study 28196076 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of patient safety incidents (PSIs) by GPs
Number of subjects: 127
Study 28196076 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational characteristics of GP practices
Number of subjects: 127
Study 28196076 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of consultation > 15 minutes
Number of subjects: 127
Study 28196076 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of receiving radiological results by fax
Number of subjects: 127
Study 28196076 — intervention group
Group type: EXPERIMENTAL
Intervention: Being in a multidisciplinary clinic
Number of subjects: 127
Study 25963412 — intervention group
Group type: EXPERIMENTAL
Intervention: DBEES mobile phone application (n = 31)
Number of subjects: 63
Study 25963412 — intervention group
Group type: COMPARATOR
Intervention: Standard paper diary (n = 32)
Number of subjects: 63
Study 24008055 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE (SC)
Number of subjects: 360
Study 24008055 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthyCHANGE (HC)
Number of subjects: 360
Study 24008055 — intervention group
Group type: COMPARATOR
Intervention: diet and physical education counseling (attention control)
Number of subjects: 360
Study 24008055 — intervention group
Group type: EXPERIMENTAL
Intervention: School environment (enriched)
Number of subjects: 360
Study 21549352 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance mat CSRT response time
Number of subjects: 47
Study 19182746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole
Number of subjects: 0
Study 17419678 — intervention group
Group type: EXPERIMENTAL
Intervention: EPF treatment (60 mg Icariin, 15 mg Daidzein, and 3 mg Genistein daily)
Number of subjects: 100
Study 17419678 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 100
Study 15131727 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype first-aid wipe with 1.0% pramoxine HCL and 0.13% benzalkonium chloride
Number of subjects: 24
Study 15131727 — intervention group
Group type: COMPARATOR
Intervention: 3% hydrogen peroxide
Number of subjects: 24
Study 15131727 — intervention group
Group type: COMPARATOR
Intervention: 70% isopropyl alcohol
Number of subjects: 24
Study 15131727 — intervention group
Group type: COMPARATOR
Intervention: Sterile 0.9% sodium chloride
Number of subjects: 24
Study 15288710 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET)
Number of subjects: 26
Study 10365355 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 2 mg 4 mL-1, 12 hourly (maximum four doses)
Number of subjects: 82
Study 10365355 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 12 hourly (maximum four doses)
Number of subjects: 82
Study 7717016 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 70
Study 7717016 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 2285296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous chloramphenicol succinate
Number of subjects: 26
Study 2285296 — intervention group
Group type: COMPARATOR
Intervention: Oral chloramphenicol capsules
Number of subjects: 26
Study 7033352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g, four times daily)
Number of subjects: 55
Study 7033352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical in appearance and taste)
Number of subjects: 55
Study 31479745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy Defibrillator (CRT‐D) implantation
Number of subjects: 1282
Study 28592240 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (PTZ)
Number of subjects: 66
Study 28592240 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 66
Study 28592240 — intervention group
Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 66
Study 26896124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 357
Study 24336096 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical site infection (SSI) rates for spinal fusion procedures
Number of subjects: 1079
Study 24336096 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical site infection (SSI) rates for other musculoskeletal procedures
Number of subjects: 1079
Study 24336096 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of SSI for clean procedures over the years
Number of subjects: 1079
Study 24336096 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors of SSI
Number of subjects: 1079
Study 21792642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) - low exposure (<1,500 mg average daily dose)
Number of subjects: 187
Study 21792642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) - high exposure (≥1,500 mg average daily dose)
Number of subjects: 187
Study 21792642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) - any exposure (<1,500 or ≥1,500 average daily dose)
Number of subjects: 187
Study 21792642 — intervention group
Group type: COMPARATOR
Intervention: No Mycophenolate mofetil (MMF)
Number of subjects: 187
Study 19278902 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinacrine (300 mg daily)
Number of subjects: 107
Study 19278902 — intervention group
Group type: COMPARATOR
Intervention: No quinacrine
Number of subjects: 107
Study 19278902 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment (random assignment)
Number of subjects: 107
Study 17140572 — intervention group
Group type: EXPERIMENTAL
Intervention: P vaginally (n = 49)
Number of subjects: 103
Study 17140572 — intervention group
Group type: COMPARATOR
Intervention: P and 4 mg E(2) orally (n = 54)
Number of subjects: 103
Study 15833569 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine and Other Substance Interaction Expectancies Questionnaire (NOSIE)
Number of subjects: 160
Study 12172224 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethrolysis
Number of subjects: 0
Study 12172224 — intervention group
Group type: COMPARATOR
Intervention: Less-invasive procedures
Number of subjects: 0
Study 9690055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive subcutaneous insulin therapy for about 12 days in a subgroup of 7 diabetic subjects
Number of subjects: 51
Study 9690055 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group of non-diabetic subjects)
Number of subjects: 51
Study 7711685 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (D, n = 40)
Number of subjects: 157
Study 7711685 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E, n = 39)
Number of subjects: 157
Study 7711685 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus Exercise (DE, n = 39)
Number of subjects: 157
Study 7711685 — intervention group
Group type: COMPARATOR
Intervention: No active intervention (C, n = 39)
Number of subjects: 157
Study 28629232 — intervention group
Group type: EXPERIMENTAL
Intervention: High mindfulness
Number of subjects: 683
Study 28629232 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low mindfulness
Number of subjects: 683
Study 28629232 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate mindfulness
Number of subjects: 683
Study 28629232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonjudgmentally aware
Number of subjects: 683
Study 30973970 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral navoximod (200 mg tablet)
Number of subjects: 24
Study 30973970 — intervention group
Group type: COMPARATOR
Intervention: Intravenous navoximod (5 mg solution)
Number of subjects: 24
Study 30973970 — intervention group
Group type: EXPERIMENTAL
Intervention: [14C]‐navoximod (200 mg/600 μCi) as an oral solution
Number of subjects: 24
Study 30973970 — intervention group
Group type: EXPERIMENTAL
Intervention: Navoximod (200 mg)
Number of subjects: 24
Study 30973970 — intervention group
Group type: EXPERIMENTAL
Intervention: Navoximod glucuronide (M28)
Number of subjects: 24
Study 29458938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue cleaning with a tongue scraper every morning for 4 weeks
Number of subjects: 58
Study 29458938 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (initially waited for 4 weeks)
Number of subjects: 58
Study 26728692 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance and NAFLD
Number of subjects: 38
Study 26728692 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes and NAFLD
Number of subjects: 38
Study 26728692 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes and no liver disease
Number of subjects: 38
Study 26728692 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 38
Study 24281563 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy
Number of subjects: 279
Study 24281563 — intervention group
Group type: COMPARATOR
Intervention: Group cognitive behavioural therapy (CBTG)
Number of subjects: 279
Study 24281563 — intervention group
Group type: COMPARATOR
Intervention: Attentional placebo (AP)
Number of subjects: 279
Study 21940785 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 21940785 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 0
Study 18448369 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction rule using three simple prognostic factors (lower than average initial pain intensity, shorter duration of symptoms, fewer previous episodes)
Number of subjects: 239
Study 18448369 — intervention group
Group type: COMPARATOR
Intervention: Clinician's prognosis judgement
Number of subjects: 239
Study 17324239 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal GTN (0.6 mg h(‐1) for 2 h, administered 24 h before IR)
Number of subjects: 66
Study 17324239 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (2 g i.v. at the time of GTN administration) + GTN
Number of subjects: 66
Study 17324239 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin (100 mg 2 h prior to GTN administration) + GTN
Number of subjects: 66
Study 17324239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 14735403 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcal vaccine (Staphypan Berna)
Number of subjects: 28
Study 14735403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11680551 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists with above-average outcomes
Number of subjects: 14
Study 11680551 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists with below-average outcomes
Number of subjects: 14
Study 11680551 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall experience in conducting psychotherapy
Number of subjects: 14
Study 11680551 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, gender, gender match, experience with cognitive-behavioral therapy (CBT)
Number of subjects: 14
Study 11680551 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of adherence and competency
Number of subjects: 14
Study 9137231 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of omega-3 fatty acids daily
Number of subjects: 28
Study 9137231 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 28
Study 7645142 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpubic penile nerve block (group 1)
Number of subjects: 31
Study 7645142 — intervention group
Group type: COMPARATOR
Intervention: No additional anesthetic procedure (group 2)
Number of subjects: 31
Study 2444961 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil infusion at 5 mg/h
Number of subjects: 0
Study 2444961 — intervention group
Group type: COMPARATOR
Intervention: Elemental calcium infusion at 3 mg/kg over 10 minutes
Number of subjects: 0
Study 29397432 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy (18 days of standardised treatment combining thermal therapy and supervised mobilisation in a thermal pool)
Number of subjects: 186
Study 29397432 — intervention group
Group type: COMPARATOR
Intervention: Control (spa therapy delayed for 6 months)
Number of subjects: 186
Study 29397432 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy
Number of subjects: 186
Study 26303644 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement training plus indicator feedback
Number of subjects: 2164
Study 26303644 — intervention group
Group type: COMPARATOR
Intervention: Indicator feedback alone
Number of subjects: 2164
Study 25603837 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat Recovery Ventilator (HRV) or Energy Recovery Ventilator (ERV)
Number of subjects: 83
Study 25603837 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 83
Study 23591294 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg · kg(‐1)
Number of subjects: 10
Study 23591294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 20570233 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 spectral-domain OCT devices and 1 time-domain OCT device
Number of subjects: 18
Study 20570233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver measurements
Number of subjects: 18
Study 20570233 — intervention group
Group type: EXPERIMENTAL
Intervention: Interoperator measurements
Number of subjects: 18
Study 20570233 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis of variance
Number of subjects: 18
Study 20570233 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectralis HRA+OCT
Number of subjects: 18
Study 20570233 — intervention group
Group type: EXPERIMENTAL
Intervention: Copernicus OCT device
Number of subjects: 18
Study 18473160 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 731
Study 18473160 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 731
Study 15845797 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg gadolinium dose
Number of subjects: 37
Study 15845797 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mmol/kg gadolinium dose
Number of subjects: 37
Study 12736843 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% T(max)
Number of subjects: 27
Study 12736843 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% T(max)
Number of subjects: 27
Study 12736843 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 10229291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid lowering therapy according to SMAC guidelines
Number of subjects: 970
Study 10229291 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension treatment
Number of subjects: 970
Study 10229291 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic control
Number of subjects: 970
Study 8671425 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG (human menopausal gonadotrophin)
Number of subjects: 218
Study 8671425 — intervention group
Group type: COMPARATOR
Intervention: HP-FSH (highly purified follicle stimulating hormone)
Number of subjects: 218
Study 8671425 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG
Number of subjects: 218
Study 8671425 — intervention group
Group type: COMPARATOR
Intervention: HP-FSH
Number of subjects: 218
Study 11188588 — intervention group
Group type: EXPERIMENTAL
Intervention: Footprint recordings on pressure-sensitive paper
Number of subjects: 42
Study 6293712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 151
Study 6293712 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin-clindamycin
Number of subjects: 151
Study 31409394 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PD-1 and CTLA-4 inhibition, tumor-directed radiation, cyclophosphamide (CTX), and L-n6-(1-iminoethyl)-lysine (L-NIL)
Number of subjects: 0
Study 31409394 — intervention group
Group type: COMPARATOR
Intervention: PD-1 and CTLA-4 blockade, and radiotherapy alone or in combination
Number of subjects: 0
Study 31409394 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX/L-NIL
Number of subjects: 0
Study 29482797 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (GI) with mustard seed application in the auricular acupoint
Number of subjects: 40
Study 29482797 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic acupuncture (GII) with bilateral needle application in the LR8 acupoint
Number of subjects: 40
Study 29482797 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of auricular and systemic acupuncture (GIII)
Number of subjects: 40
Study 29482797 — intervention group
Group type: COMPARATOR
Intervention: Control group (GIV) with mustard seed application in an acupoint not linked to muscle tension
Number of subjects: 40
Study 27094037 — intervention group
Group type: COMPARATOR
Intervention: Group C (high alcohol intake)
Number of subjects: 92
Study 27094037 — intervention group
Group type: COMPARATOR
Intervention: Group B (moderate alcohol intake)
Number of subjects: 92
Study 27094037 — intervention group
Group type: EXPERIMENTAL
Intervention: Global RV systolic parameters
Number of subjects: 92
Study 24476106 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle of Security (COS) Intervention
Number of subjects: 80
Study 24476106 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 80
Study 22989819 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg) plus Hydrochlorothiazide (12.5 mg)
Number of subjects: 164
Study 20589313 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC1779 (4-5 microg/ml)
Number of subjects: 2